공고 • Jul 31
Stevanato Group Announces Marketing Authorizations for Liraglutide-Based Combination Products Incorporating Alina Pen Injector in Multiple European Countries Stevanato Group S.p. A announced that liraglutide-based combination products incorporating Stevanato Group’s proprietary Alina pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Marketing Authorization Holders. The approved configurations include Alina 30, developed for liraglutide-based therapies for diabetes, and Alina 50, designed for liraglutide-based weight management applications. Both variants are part of Stevanato Group's broader Alina variable-dose pen injector platform, which offers multiple pre-configured variants for GLP-1s and other injectable therapies. Alina features a dial-a-dose mechanism with visual, audible, and tactile feedback during dose selection and injection, and compatibility with ISO standard 3 mL glass cartridges. The platform has been designed to support manufacturing scalability, and integration into existing pharmaceutical fill and finish and final assembly supply chains. These authorizations come at a time when injectable therapies are playing an increasingly important role in healthcare, driven by the ongoing expansion of GLP-1 treatments and the broader shift towards patient-centric models of care and self-administration. Through its proprietary device portfolio – including Alina (variable-dose, pen injector), Deora (fixed-dose, pen injector), Aidaptus (autoinjector) and Vertiva (on-body delivery system) – Stevanato Group is expanding its drug delivery capabilities to support pharmaceutical and biotechnology companies developing next-generation therapies. Alina is manufactured within Stevanato Group's Drug Delivery Systems operations and leverages the Company's integrated expertise across pharmaceutical glass containers, engineering technologies, analytical services and device manufacturing. The platform has been designed to offer pharmaceutical partners a flexible and production-ready solution capable of supporting commercial-scale deployment. Alina is a variable-dose, disposable pen injector platform designed for subcutaneous drug delivery. The platform can accommodate doses from 0.01 mL up to 0.75 mL and includes multiple pre-configured variants developed for GLP-1 and other injectable therapies. Alina combines familiar handling, enhanced dose readability and flexible customization options to support a wide range of therapeutic requirements. 공고 • Jul 21
Stevanato Group S.p.A. to Report Q2, 2026 Results on Aug 04, 2026 Stevanato Group S.p.A. announced that they will report Q2, 2026 results at 6:30 AM, US Eastern Standard Time on Aug 04, 2026 공고 • Jun 10
Stevanato Group Introduces Deora Pen Injector Platform for Subcutaneous Delivery in Diabetes and Weight Management Stevanato Group S.p.A. introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs. Deora™ is Stevanato Group’s multi-use, fixed-dose pen injector designed for subcutaneous drug delivery in therapies such as diabetes and weight management. Featuring an intuitive pull-push mechanism, the device simplifies dose administration by eliminating the need for manual dose selection: users pull to set the dose and push to inject, supporting consistent delivery across multiple administrations. The platform accommodates fixed-dose volumes up to 0.75 mL and is compatible with standard 1.5 mL and 3 mL cartridges, offering flexibility across a range of therapeutic applications. Engineered with patient usability in mind, Deora™ provides tactile, visual, and audible feedback during operation, helping reduce common sources of use error. Its architecture is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing for pharmaceutical partners. Deora™ is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism for dose setting and delivery: the user pulls to set the dose, then pushes to inject. This intuitive sequence eliminates the need for manual dose selection, reducing common sources of use error and supporting consistent drug delivery across multiple administrations. The platform is compatible with standard 1.5 mL and 3 mL cartridges and accommodates fixed-dose volumes up to 0.75 mL. The device architecture provides flexibility across multiple fixed-dose configurations while minimizing the need for design changes across variants. In addition, it is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing. Deora™ further expands Stevanato Group’s proprietary portfolio of drug delivery devices, providing a solution designed for multi-dose therapies requiring consistent administration and ease of use in a familiar pen format. Customers can now choose from different hand-held device platforms – Alina®, Aidaptus®, and Deora™ – to address a broad range of therapeutic needs. Deora™ leverages Stevanato Group’s established manufacturing capabilities, with production aligned to support future commercialization. Drawing on its end-to-end expertise across glass manufacturing, analytical services, and device engineering, Stevanato Group offers fully integrated solutions that can simplify development for pharmaceutical partners. Together, these characteristics position Deora™ as a platform intended to support partners as they advance early development programs and prepare for future scale-up. 공고 • Jun 05
Stevanato Group S.p.A. Approves Dividend on Class A Share Stevanato Group S.p.A. at its Ordinary and Extraordinary Meeting of Shareholders held on May 26, 2026 approved distribution of dividends in the amount of EUR 0.054 for each outstanding Class A and ordinary share of the Company, net of the treasury shares. 공고 • May 30
Stevanato Group S.p.A. Appoints Peter Soelkner as Non-Executive Director, Effective 26 May 2026 Oxford Biomedica plc announced that pursuant to UK Listing Rules 6.4.9R, Peter Soelkner, Vice Chair and Independent Non-Executive Director has been appointed as a Non-Executive Director of Stevanato Group S.p.A, a NASDAQ listed company with effect from 26 May 2026. 공고 • May 12
Stevanato Group S.p.A., Annual General Meeting, May 26, 2026 Stevanato Group S.p.A., Annual General Meeting, May 26, 2026. 
